Physician profile
Ferdinant Saran
NPI 1245280007
$2,317.35
in general payments reported to CMS, 2019-2025
21 companies · $802 in 2025
The $802 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $120 · 2021: $56.23 · 2022: $239 · 2023: $341 · 2024: $296 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $544.87 | 2019-2025 | Evenity, Repatha, Otezla |
| Ardelyx, INC. | $291.70 | 2024-2025 | Ibsrela |
| Astellas Pharma US INC | $251.43 | 2019 | |
| Abbott Laboratories | $218.81 | 2022 | |
| Lilly USA, LLC | $188.97 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Genzyme Corporation | $124.77 | 2023 | |
| Philips North America LLC | $119.77 | 2020 | |
| Abbvie INC. | $100.62 | 2021-2025 | |
| Exact Sciences Corporation | $86.74 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $47.15 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $43.61 | 2025 | Rexulti |
| Novo Nordisk INC | $42.94 | 2019 | |
| Abiomed | $35.32 | 2025 | |
| Novartis Pharmaceuticals Corporation | $34.47 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.78 | 2023 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $32.17 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $30.00 | 2023 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $24.54 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $24.39 | 2019 | |
| Idorsia Pharmaceuticals US INC | $23.71 | 2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ferdinant Saran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.